Dr. Jay G. Courtright, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 316
Licensed in Texas since 2003, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license L6848 (first issued 2003; active) -
Hematology & Oncology Physician
TX license L6848 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical City Dallas Hospital Dallas, TX
Medical groups
- Catholic Health Initiatives Colorado (1,225 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 316
- Services billed
- 36,210
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Blood test, comprehensive group of blood chemicals | 635 | 228 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 547 | 204 |
| Insertion of needle into vein for collection of blood sample | 482 | 207 |
| Established patient office or other outpatient visit, 30-39 minutes | 365 | 115 |
| Injection, dexamethasone sodium phosphate, 1 mg | 324 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 259 | 165 |
| Injection, granisetron hydrochloride, 100 mcg | 170 | 11 |
| Lactate dehydrogenase (enzyme) level | 165 | 74 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 146 | 72 |
| Ferritin (blood protein) level | 108 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Dallas, TX | 131 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 58 |
| Xarelto (rivaroxaban) Other prescribers in Dallas, TX | 44 |
| Ondansetron Hcl Other prescribers in Dallas, TX | 37 |
| Anastrozole Other prescribers in Dallas, TX | 33 |
| Acyclovir Other prescribers in Dallas, TX | 26 |
| Prednisone Other prescribers in Dallas, TX | 26 |
| Alprazolam Other prescribers in Dallas, TX | 22 |
| Dexamethasone Other prescribers in Dallas, TX | 21 |
| Hydroxyurea Other prescribers in Dallas, TX | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 18 payments worth $1,521 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,106 |
|---|---|
| Caris Mpi, Inc. | $179 |
| Janssen Biotech, Inc. | $119 |
| Carter Bloodcare | $64.43 |
| Adc Therapeutics America, Inc. | $52.02 |
| Long term medical supply or device loan | $1,097 |
|---|---|
| Food and Beverage | $425 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $63,434 in research payments for these studies, mostly to the institutions running them.
- Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865 - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796 - An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies
Merck Sharp & Dohme LLC - A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Terminated · NCT04752332 - A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously…
E.r. Squibb & Sons, L.l.c. - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca Pharmaceuticals LP - Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.